MedTrace Logo

Renal Function and Pharmacogenetics in Renal Transplant Recipients Converted From Tac BID to Tac OD

NCT01884480 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2014-11-19

No results posted yet for this study

Summary

In Kidney transplant recipients Once daily Tacrolimus has the poteb\]ntial advantage of better adnerence, and perhpas improvement in reanl function compred with the twice daily tacrolimus formulation.

Our center has the largest experience in North America with once-daily tacrolimus ( advagraf) in Renal transplant recipients.

Recently we converted \~500 stable patients from the twice daily to once-daily tacrolimus.

We are interested in:

1. change in renal function
2. dose changes based on ethnic diveristy
3. dose changes based on pharmacogenetics

This will helpnus understand better ways to utilize this anti-rejection medication

Conditions

  • Real Function Post Conversion From Prograf to Advagraf
  • Examin Ethnicity and Pharmacogenetics of the Cohort Requiring Dose Adjustment Post-conversion

Sponsors & Collaborators

  • Unity Health Toronto

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01884480 on ClinicalTrials.gov